Gen2B

Gen2B is a **preclinical monoclonal antibody program from Gen2 Neuroscience** directed against **toxic extracellular forms of tau** for the treatment of tauopathies including **Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy**. The program is described by the company as its lead anti-tau effort and is designed to preferentially bind disease-associated extracellular tau while sparing abundant normal non-toxic tau, with the goal of blocking uptake and spread of pathogenic tau species between neurons and thereby slowing neurodegeneration. In preclinical research, Gen2B has been described as recognizing a tau epitope in the R' domain immediately C-terminal to the microtubule-binding region and has shown activity in neutralizing synaptotoxic extracellular tau species and restoring long-term potentiation in animal models.

Other names

Gen2B anti-tau antibodyGen-2B anti-tau antibodyGen 2B anti-tau antibody